Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences
Open accessThe DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index; 26 of the 102 sources its claims cite were checked for support.
Abstract
The prevalence of sarcopenic obesity is increasing worldwide, particularly amongst aging populations. Insulin resistance is the core mechanism of sarcopenic obesity and is also associated with variable cardiometabolic diseases such as cardiovascular disease, type 2 diabetes mellitus, and non-alcoholic fatty liver disease. Fat accumulation in muscle tissue promotes a proinflammatory cascade and oxidative stress, leading to mitochondrial dysfunction, impaired insulin signaling, and muscle atrophy. To compound the problem, decreased muscle mass aggravates insulin resistance. In addition, the crosstalk between myokines and adipokines leads to negative feedback, which in turn aggravates sarcopenic obesity and insulin resistance. In this review, we focus on the molecular mechanisms linking sarcopenic obesity and insulin resistance with various biological pathways. We also discuss the impact and mechanism of sarcopenic obesity and insulin resistance on cardiometabolic disease.
Overview
CoChat Summary
TL;DR
This narrative review argues that insulin resistance is the core mechanism linking sarcopenic obesity to cardiometabolic disease through fat accumulation, inflammation, mitochondrial dysfunction, and impaired insulin signaling in skeletal muscle. It further discusses how myokine–adipokine crosstalk and hormonal changes aggravate sarcopenic obesity and its cardiovascular, metabolic, and hepatic consequences.
Key findings
- Sarcopenic obesity is associated with a 2–3 times higher risk of functional disability than either sarcopenia or obesity alone, and it combines muscle loss with fat accumulation, including intramyocellular lipid, intermyocellular adipose tissue, and peri-muscular adipose tissue.
- In skeletal muscle, lipid intermediates such as DAG and ceramides activate PKC, JNK, IKK/NF-kB, and related pathways, causing serine/threonine phosphorylation of insulin receptor/IRS-1, impaired PI3K/Akt signaling, and reduced GLUT4 translocation; this impairs glucose uptake and promotes muscle atrophy.
- Inflammation is central: adipose tissue macrophage staining is approximately 10% in lean subjects but up to 50% in obese subjects, and proinflammatory cytokines such as TNF-α, IL-1β, and IL-6 contribute to insulin resistance, muscle atrophy, and cardiometabolic disease.
- Sarcopenic obesity and insulin resistance are linked clinically to atherosclerosis/cardiovascular disease, chronic heart failure, type 2 diabetes mellitus, metabolic syndrome, and NAFLD; skeletal muscle accounts for approximately 80–90% of postprandial glucose uptake, making muscle insulin resistance crucial in diabetes pathogenesis.
Methods
- Design: narrative review of molecular and clinical literature on sarcopenic obesity, insulin resistance, and cardiometabolic disease.
- Data/sample: no primary cohort or experimental sample; the paper synthesizes prior human, animal, and in vitro studies and cites clinical examples, including studies on carotid intima-media thickness, myocardial infarction, chronic heart failure, type 2 diabetes, metabolic syndrome, and NAFLD.
- Main analysis: thematic synthesis of mechanisms, including fat accumulation, inflammation, sex/growth hormone deficiency, skeletal muscle insulin signaling pathways, myocyte–adipocyte crosstalk, and pathophysiological links to cardiometabolic diseases.
Limitations
- The paper states that the definition of sarcopenic obesity has not been universally established and that different diagnostic criteria have different clinical implications.
- The paper repeatedly notes conflicting or insufficient evidence, including controversy over irisin and exercise, adiponectin’s clinical role, JAK/STAT signaling in muscle insulin resistance, and whether obesity itself is more predictive than sarcopenia for metabolic syndrome in some studies.
- Evident from the text: as a narrative review without a stated systematic search strategy, risk-of-bias assessment, or meta-analysis, it cannot quantify effect sizes or resolve heterogeneity across the cited studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
20 Valid · 4 Not valid · 62 Not checked · 9 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“A British regional health study reported that older subjects with sarcopenic obesity had the highest cardiovascular mortality [113].”
§ Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences > 4. Pathophysiological Link among Cardiometabolic Disease, Sarcopenic Obesity, and Insulin Resistance > 4.1. Atherosclerosis and Cardiovascular Disease
What the sources say
- Disputedcites [113] Atkins J.L. Whincup P.H. Morris R.W. Lennon L.T. Papacosta O. Wannamethee S.G. Sarcopenic obesity and risk of cardiovascular disease and mortality: A population-based cohort study of older men J. Am. Geriatr. Soc. 2014 62 253 260 10.1111/jgs.12652 24428349 PMC4234002 sourceExperimental — accuracy not yet measured
Our copy (Abstract Conclusion; Discussion, and Discussion > Strengths and Limitations) states the opposite for cardiovascular mortality: 'Sarcopenic obese men had the highest risk of all-cause mortality but not CVD mortality,' and the Abstract Results add that CVD mortality risk was significantly greater in sarcopenic and obese but NOT sarcopenic obese men. The only point at which the sarcopenic obese group topped CVD mortality was the age-adjusted model, which lost significance after adjustment for lifestyle variables (Results). The highest-risk finding the paper reports for sarcopenic obesity is all-cause mortality (HR = 1.72, 95% CI = 1.35–2.18), so the claim substitutes CVD mortality for all-cause mortality; it also generalises 'older men' (British Regional Heart Study, aged 60–79) to 'older subjects'. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This complex disorder results in a 2–3 times higher risk of functional disability than either sarcopenia or obesity alone [14].”
§ Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences > 2. Sarcopenia and Sarcopenic Obesity > 2.1. Definition
What the sources say
- Partly supportedcites [14] Rolland Y. Lauwers-Cances V. Cristini C. Abellan van Kan G. Janssen I. Morley J.E. Vellas B. Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women: The EPIDOS (EPIDemiologie de l’OSteoporose) Study Am. J. Clin. Nutr. 2009 89 1895 1900 10.3945/ajcn.2008.26950 19369381 sourceExperimental — accuracy not yet measured
The Results (page unavailable) report roughly 2–3 times higher odds of difficulty with several physical tasks for sarcopenic-obese women than for purely sarcopenic women. Compared with purely obese women, however, the difference was statistically significant only for going down stairs. The study measured self-reported functional difficulties in a cross-sectional sample, not a general 2–3-fold higher risk of developing disability than either group. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Intermyocellular adipose tissue (IMAT) and IMCL secrete myostatin, CCL2, TNF-α, IL-1β, and IL-6, thus inducing IR and lipotoxicity, which is discussed in the next section [30].”
§ Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences > 2. Sarcopenia and Sarcopenic Obesity > 2.2. Molecular Mechanism of Sarcopenic Obesity
What the sources say
- Partly supportedcites [30] Rivas D.A. McDonald D.J. Rice N.P. Haran P.H. Dolnikowski G.G. Fielding R.A. Diminished anabolic signaling response to insulin induced by intramuscular lipid accumulation is associated with inflammation in aging but not obesity Am. J. Physiol. Regul. Integr. Comp. Physiol. 2016 310 R561 R569 10.1152/ajpregu.00198.2015 26764052 PMC4867383 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) links lipid accumulation in obesity to inflammation and secretion of TNF-α, IL-1β, and IL-6. It does not say that IMAT and IMCL themselves secrete those cytokines or myostatin and CCL2, nor does it establish that such secretion induces insulin resistance and lipotoxicity. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The amount of PMAT is correlated with the severity of muscle atrophy [31].”
§ Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences > 2. Sarcopenia and Sarcopenic Obesity > 2.2. Molecular Mechanism of Sarcopenic Obesity
What the sources say
- Supportedcites [31] Zhu S. Tian Z. Torigoe D. Zhao J. Xie P. Sugizaki T. Sato M. Horiguchi H. Terada K. Kadomatsu T. Aging-and obesity-related peri-muscular adipose tissue accelerates muscle atrophy PLoS ONE 2019 14 e0221366 10.1371/journal.pone.0221366 31442231 PMC6707561 source
The Results section, “PMAT accumulation increases with muscle atrophy in aged mice,” reports that mice with at least 5% PMAT had lower muscle mass and muscle-fiber cross-sectional area than mice with less than 5% PMAT. The authors describe the degree of PMAT deposition as associated with progression of muscle atrophy in aged mice. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Low GH levels reduce IGF1 action by sequentially downregulating the PI3K-AKT/PKB-mTOR pathway, which induces protein synthesis in muscles [49].”
§ Sarcopenic Obesity, Insulin Resistance, and Their Implications in Cardiovascular and Metabolic Consequences > 2. Sarcopenia and Sarcopenic Obesity > 2.2. Molecular Mechanism of Sarcopenic Obesity
What the sources say
- Partly supportedcites [49] Egerman M.A. Glass D.J. Signaling pathways controlling skeletal muscle mass Crit. Rev. Biochem. Mol. Biol. 2014 49 59 68 10.3109/10409238.2013.857291 24237131 PMC3913083 sourceExperimental — accuracy not yet measured
The section on IGF1/PI3K/Akt hypertrophy signaling (page not provided) describes IGF1 activating PI3K/Akt and mTORC1 signaling in skeletal muscle; its Figure 1 caption links that signaling to protein synthesis. The passages do not say that low growth hormone (GH) levels reduce IGF1 action or downregulate this pathway. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
43 more claims · 9 with their cited sources checked
Create a free account to see all 95 claims and to verify the 76 references still open.
- It may state two separate claims as one. 44
- Probably not a substantial claim. 5
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Various myokines released from active muscles act as signalling mediators between skeletal muscle and other vital organs, such as the liver, fat, and brain.[ 5 ]”
From Pathogenesis of sarcopenia and the relationship with fat mass: descriptive review (2022) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Secondly, metabolic disorders including cardiometabolic syndrome (CMS), diabetes, cardiovascular disease (CVD), and cancer are common comorbidities of SO (54, 55).”
From Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments (2020) · cites this paper as [54]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Obesity can independently lead to loss of muscle mass and function, due to the negative impact of adipose tissue-dependent metabolic derangements, such as oxidative stress, in fl ammation, and insulin resistance, all which negatively affect muscle mass [6].”
From Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement (2022) · cites this paper as [6]
In the citing paper
“Aging-associated increases in visceral fat and reduced muscle mass are correlated with multiple adverse cardiometabolic effects and contribute to poor health outcomes (119).”
From Health Consequences of Sarcopenic Obesity: A Narrative Review (2020) · cites this paper as [119]
In the citing paper
“Obesity can independently lead to loss of muscle mass and function, due to the negative impact of adipose tissue-dependent metabolic derangements, such as oxidative stress, inflammation and insulin resistance, all of which negatively affect muscle mass [6].”
From Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement (2022) · cites this paper as [6]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818 · cited 3×
“EWGSOP2 [2] Use the SARC-F questionnaire to find subjects with sarcopenia Decreased muscle mass and Decreased muscle strength or performance NA”
BackgroundMethodObesity is associated with macrophage accumulation in adipose tissue
Weisberg, S. P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R. L., & Ferrante, A. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200319246 · Cited by 10,041 · cited 1×
“In adipose tissue from lean subjects, approximately 10% of cells stained positive for macrophages, but in obese subjects, this number increased to up to 50% [38].”
BackgroundInflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773 · cited 1×
“Atherogenesis is a complicated process that includes oxidative stress, inflammation, endothelial dysfunction, vascular proliferation, and thrombosis [104].”
BackgroundIncreased oxidative stress in obesity and its impact on metabolic syndrome
Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama, O., Makishima, M., Matsuda, M., & Shimomura, I. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21625 · Cited by 5,508 · cited 2×
“It causes the dysregulation of adipocytokines, such as adiponectin, PAI-1, IL-6, and MCP-1, leading to metabolic syndrome [134].”
BackgroundA PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis
Boström, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J. C., Rasbach, K. A., Boström, E. A., Choi, J. H., Long, J. Z., et al. (2012) · Nature · doi:10.1038/nature10777 · Cited by 4,810 · cited 1×
“Irisin is a PPARγ-coactivator-1α (PGCα)-dependent myokine that stimulates browning in subcutaneous adipose tissues and induces increased energy expenditure, which improves obesity and IR through the MAPK and ERK pathways [92,93].”
BackgroundYamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238 · cited 1×
“Thus, it facilitates insulin sensitivity by increasing glucose uptake in skeletal muscle and by stimulating fatty acid oxidation through activation of the 5′-AMP-activated protein kinase (AMPK) signaling pathway [100].”
BackgroundSarcopenia in Asia: Consensus Report of the Asian Working Group for Sarcopenia
Chen, L.-K., Liu, L.-K., Woo, J., Assantachai, P., Auyeung, T.-W., Bahyah, K. S., Chou, M.-Y., Chen, L.-Y., Hsu, P.-S., Krairit, O., et al. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.11.025 · Cited by 4,051 · cited 3×
“Sarcopenia results in a decreased metabolic rate, low physical activity, and myokine deficiency, which collectively leads to the proinflammatory effect, and exacerbates obesity.”
BackgroundInfluentialSarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 2×
“Moreover, obesity accompanies the accumulation of lipids in the liver, thus aggravating insulin resistance in hepatocytes [141].”
BackgroundA Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564 · cited 1×
“Inflammation due to sarcopenic obesity results in reduced NO, cyclic guanosine monophosphate (cGMP), and protein kinase G (PKG) activity in cardiomyocytes, leading to LV hypertrophy and stiffness [120].”
Background
Research works printed but not linked: 1
- White A.T. Schenk S. Knockout of STAT3 in skeletal muscle does not enhance insulin action Diabetologia 2013 56 S250
Cited by
Items 301–400 of 400
Antyukh, K. Y., Григоренко, Е. А., Sheptulina, A. F., Drapkina, O. M., & Митьковская, Н. П. (2023) · Кардиология в Беларуси · doi:10.34883/pi.2023.15.4.007 · Cited by 1
Nashawi, M., Ahmed, M. S., Ahmad, M. I., Issa, O., & Abualfoul, M. (2021) · Austin Journal of Pharmacology and Therapeutics · doi:10.26420/austinjpharmacolther.2021.1139
“testosterone in the sarcopenic obese phenotype [70].”
Backgroundde Souza, E. D. S., Melo, D. D. A., Silva, M. G. C., Pinho, C. P. S., de Carvalho, T. R., Duarte, R. D. S., de Almeida, I. K. G., Silva, R. P. P., Maio, R., & de Lemos, M. D. C. C. (2022) · Research Society and Development · doi:10.33448/rsd-v11i12.34715 · Cited by 1
Asús, N. (2022) · Diabetes & Obesity International Journal · doi:10.23880/doij-16000263
Musculoskeletal and immunological considerations
Fettke, G., Kaplan, B., Baker, S., & Rice, S. M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821617-0.00004-8 · Cited by 1
Bone density in patients with nonfunctional adrenal incidentaloma
Kültür, T., Güngüneş, A., Ceylan, Ş. D., Karatlı, S., İnal, M., & Göncüoğlu, A. (2023) · Intercontinental Journal of Internal Medicine · doi:10.51271/icjim-0018
Farsi, D. N., McKay, G. J., Linden, G. J., McAlinden, M., Teeling, J. L., Passmore, P., Holmes, C., Patterson, C., McGuinness, B., & McEvoy, C. T. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4660405
Wu, J., Feng, Z., Duan, J., Li, Y., Deng, P., Wang, J., Yang, Y., Meng, C., Wang, W., Wang, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23672453
Каретникова, В. Н., Геннадьевна, Н. А., Carpova, E. I., & Барбараш, О. Л. (2024) · Cardiosomatics · doi:10.17816/cs624809
Li, N., Chen, S., He, Y., He, W., Wang, Q., Liu, S., Liu, T., & Fang, H. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4830792
Muscle Organoid and Assembloid Systems
Soydan, H. E., & Doğan, A. (2024) · Advances in experimental medicine and biology · doi:10.1007/5584_2024_816 · Cited by 1
Lan, J., Guo, H., Zou, J., Xue, J., Ni, H., Wang, L., Ren, T., Chai, S., Jiang, H., Gou, C., et al. (2024) · Portal hypertension & cirrhosis · doi:10.1002/poh2.89
Тамерланович, Ц. Т., Skripnikova, I. A., Kosmatova, O. V., & Куруглиевна, Я. Э. (2024) · Russian Journal of Preventive Medicine · doi:10.17116/profmed202427121128
BIA법에 의한 농촌지역 남성 장년층의 비만도 및 근감소증에 따른 체구성, 형태 및 체력변인에 대한 비교분석 연구
박, 재., 권, 대., & 송, 영. (2024) · 한국체육학회지 · doi:10.23949/kjpe.2024.11.63.6.29
Chainikova, M. A., Kurmaev, D. P., Bulgakova, S. V., & Treneva, E. V. (2025) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-228-8-76-88 · Cited by 3
Sarkopene Adipositas im Alter: Ursachen, Folgen und Behandlungsansätze
Rippl, M., Drey, M., & Schluessel, S. (2025) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2492-9415
“Dieses produ-ziert pro-inflammatorische Zytokine, die sogenannten Adipokine, wie TNF-alpha, IL-6 und IL-1 und setzt dadurch pro-apoptotische Prozesse in Gang [10].”
InfluentialShi, M., Fan, S., Sun, L., Chen, X., & Zhang, G. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.04.018 · Cited by 1
“SO contributes to CVD primarily through its detrimental effects on metabolic health, particularly insulin resistance (IR), which induces endothelial dysfunction and vascular damage [46 e 50].”
Islam, M. A., Gu, W., Song, Y., Xu, Y., & Xu, H. (2025) · Acta Materia Medica · doi:10.15212/amm-2024-0091
“Hence, inflammaging and metaflammation are central to sarcopenic obesity [12, 13].”
Clinical Significance of Skeletal Fat‐to‐Muscle Ratio in Idiopathic Hyperaldosteronism
Jiang, Y., Li, D. X., Cao, C. C., Feng, W., Liu, R., Xu, Y., & Cao, C. (2025) · Clinical Endocrinology · doi:10.1111/cen.15274
Chen, Y., Hu, D.-S., Zhang, B., Hong, H.-Z., Lin, M., Ye, B., Dong, Y., Wang, R., Cui, G.-W., Gao, Z.-H., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5347807
E-book Mulheres no climatério: desafios físicos, emocionais e sociais
Rocha, J. S. B., Caldeira, A. P., Rossi-Barbosa, L. A. R., & Maia, L. C. (2025) · Amplamente Cursos e Formação Continuada eBooks · doi:10.47538/ac-2025.14
Further Insights into Ambulatory Blood Pressure Modulation by Age and Body Weight
Xu, J., & Zhu, M. L. (2025) · Angiology · doi:10.1177/00033197251365427
Li, X., Yang, L., Gao, Y., Chen, K., Tang, M., Niu, H., Sun, Q., & Zhang, S. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01937-9 · Cited by 2
“Secondly, diabetic patients are often accompanied by insulin resistance and malnutrition, which further aggra-vates the reduction of muscle mass [29–31].”
管, 宇. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15102906
Du, X., Chenhang, Y., Huang, R., Zeng, Y., & Mao, S. (2025) · Journal of Science in Sport and Exercise · doi:10.1007/s42978-026-00375-x
Beyond BMI: Metabolic Signatures of Obstructive Coronary Artery Disease in a Sudanese Cohort
Elhakeem, R. F., Lutfi, M. F., Abdrabo, A. A., Ali, A. B., & Sukkar, M. Y. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238345
Feng, B., Qin, Y., Cai, Q., & Huang, D. (2025) · BMC Geriatrics · doi:10.1186/s12877-025-06688-w
“Given that insulin resistance is a core mechanism of SO [39], these abnormalities could further affect muscle mass and function, ultimately leading to SO.”
Damanti, S., Citterio, L., Zagato, L., Brioni, E., Magnaghi, C., Simonini, M., De Lorenzo, R., Ruggiero, M., Santoro, S., Senini, E., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26756371
Wu, J., Feng, Z., Duan, J., Li, Y., Deng, P., Wang, J., Yang, Y., Meng, C., Wang, W., Wang, A., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23672450
Zhang, J., Na, X., Li, Z., Ji, J. S., Li, G., Yang, H., Yang, Y., Tan, Y., Zhang, J., Xi, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26696789
Lu, Y., Tian, J., Liangyu, W., Xia, Q., & Zhu, Q. (2023) · Figshare · doi:10.6084/m9.figshare.23550478
Fu, X., Zhao, J., Meng, H., Wang, M., & Qiao, H. (2025) · Frigid Zone Medicine · doi:10.1515/fzm-2025-0026
“It is well established that hepatic lipid dysregulation contributes to lipotoxicity and inflammation, which are central to the development of hepatic steatosis in both T2DM and MASLD [6-7] .”
Kim, S. (2025) · Journal of Korean Diabetes · doi:10.4093/jkd.2025.26.4.238 · Cited by 1
Song, C., Guo, D., Chen, S., Ran, X., Leng, L., Bai, Y., Yang, J., & Lin, Z. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05480-3
“As the primary site for insulin-mediated glucose disposal, dysfunctional or diminished muscle mass may serve as a key driver of insulin resistance (IR), a core mechanism in cardiometabolic disease [11, 12].”
方, 艳. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.161069
Khan, A. A., Sattar, M. I., Mahmood, S. A., & Siddiqui, M. A. S. (2026) · Nutrition and Health · doi:10.1177/02601060251412680
“A sedentary lifestyle might also pose a clinical dif fi culty for those with this condition (Hong and Choi, 2020).”
Mechanisms of insulin resistance in elderly sarcopenia patients and their bidirectional relationship
Du, H., Qu, Y., Huai, Z., & Wang, S. (2026) · Geriatric Nursing · doi:10.1016/j.gerinurse.2026.103907
Shao, H., Wang, Y., Park, Y.-K., & Jung, H. W. (2026) · Nutrients · doi:10.3390/nu18030429
“This pathological milieu collectively suppresses mitochondrial biogenesis and protein synthesis while accelerating protein degradation, ultimately leading to muscle fiber atrophy, disrupted muscle fiber organization, and declines in muscle mass, strength, and endurance [26,27].”
Lee, D., Heo, D., Ryu, J., Kim, K. S., & Kim, M. (2026) · Research Square · doi:10.21203/rs.3.rs-8852127/v1
HOMA-IR Values in Overweight and Obesity Subjects With and Without Sarcopenia
Suhardi, F. L., Aman, A. M., Sudarso, A., Bakri, S., Rasyid, H., & Seweng, A. (2026) · F1000Research · doi:10.12688/f1000research.177884.1
Ding, R., Zhou, M., Guan, K., Xie, L., Zhang, Y., Chen, Q., Li, J., Shan, L., & Lu, H. (2026) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000003096
Frailty, sarcopenia, and diabetes: Managing physical decline
Hajam, Y. A., Bhatti, N., Kaur, A., Ahmed, S., & Rai, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44665-8.00005-5
Chan, K. C., Hii, H., Kuo, H., Wang, C., Cheng, K., Ou, H., & Wu, H. (2026) · Acta Physiologica · doi:10.1111/apha.70182
“The condition of sarcopenic obesity represents the synergistic impact of excess adiposity and muscle wasting, with insulin resistance serving as a core pathophysiological mechanism [18].”
Wu, Y., Zhang, Y., Li, Y. C., Tin, H., Li, Y., & Yan, X. (2026) · Obesity Reviews · doi:10.1111/obr.70130
Schimmel, M. D., Junge, J. Y., Hansen, E. B., Hyldelund, N. B., & Kidmose, U. (2026) · Food Quality and Preference · doi:10.1016/j.foodqual.2026.105923
VARIOUS BODY COMPOSITION DISORDERS IN ELDERLY PATIENTS WITH ATHEROSCLEROSIS OF VASCULAR BEDS
Цыганкова, Д. П., Bazdyrev, E. D., Анатольевич, Ц. Д., Miroshnichenko, S. V., Геннадьевна, Н. А., Каретникова, В. Н., Евгеньевна, К. К., Voronina, E. A., & Barbarash, O. L. (2026) · Complex Issues of Cardiovascular Diseases · doi:10.17802/2306-1278-2025-14-6s-83-93
Gong, S., Dong, G., Li, N., He, M., Liang, Q., Lin, L., Gao, Z., Liu, X., & Shi, L. (2026) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-026-09743-8
“The association between muscle strength decline and diabetes may be due to insulin resistance in skeletal muscle [53], which exacerbates muscle weakness and impairs neural pathways involved in motor control, thereby accelerating the development of dynapenia [54].”
Shang, J., Yan, K., Liu, L., Jin, C., Ran, L., Zhang, J., Wu, P., Meng, F., Zeng, X., Cao, X., et al. (2026) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2026.107025
Zhang, X., Fan, Y., Hua, L., Zhou, Y., & Sun, Q. (2026) · Nutrients · doi:10.3390/nu18081267 · Cited by 3
“Evidence shows that reduced physical activity can lead to adipose tissue hypertrophy and chronic inflammation, and this chronic inflammatory state can exacerbate muscle tissue atrophy [61,62].”
Afşar, B., Kanbay, M., & Afşar, R. E. (2026) · Clinical Nutrition · doi:10.1016/j.clnu.2026.106674
Iradata, F. A., Ahmad, Firdayani, Kartika, I. R., Waluyo, D., Ariyani, T., Prabandari, E. E., Nugroho, N. B., & Iresha, M. R. (2026) · Biointerface Research in Applied Chemistry · doi:10.33263/briac162.045
Control of muscle mass during growth and aging: Clinical targets and pathways
Sánchez, S. S., da Fonseca, G. W. P., & von Haehling, S. (2026) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2026.102114
Cattafesta, M., & Salaroli, L. B. (2026) · BMC Nephrology · doi:10.1186/s12882-026-05032-7
“It should be noted that dynapenia, characterized by a decline in muscle strength and power [13], may be accompanied by an increase in abdominal fat mass attributable to aging, a lower metabolic rate, or myokine deficiency [12].”
Sajedizadeh, M., Bazmi, S., Davoudi, S. H., Razaz, J. M., Farjam, M., & Homayounfar, R. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02923-2
“Previous studies have consistently reported an inverse relationship between skeletal muscle mass and insulin resis - tance [10, 11], suggesting that metabolic dysfunction con - tributes to the development of sarcopenia [12–14].”
Ding, Y., Wang, Z., Shen, T., Hailili, G., Yan, M., Liu, X., He, D., & Yuan, C. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08223-w · Cited by 1
“IR can drive frailty progression by inducing metabolic disturbances, oxidative stress, endothelial dysfunction, and persistent inflammation [42, 43].”
Sun, Y., Yu, X., Zhang, T., Bai, C., Zhang, L., & Ma, Y. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1813601
“Relevant studies suggest that sarcopenia may promote atherosclerosis and other cardiovascular diseases through common mechanisms such as pro-inflammatory responses, oxidative stress, and IR, thereby forming a vicious cycle (26–28).”
Plasma Pentosidine and Sarcopenia: Beyond Muscle Mass Alone
Liu, G. (2026) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.70582
Ma, L., Abudoureyimu, M., Feng, Z. Q., Dong, J. J., Cui, J. Y., Cai, C., & Yalikun, P. (2026) · Research Square · doi:10.21203/rs.3.rs-6284574/v1
Tang, J., Xu, P., Guo, J., & Hao, P. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2679841
“Evidence indicates that insulin resistance independently contributes to the pathogenesis of diverse cardiovascular disorders [30,31] and has also been associated with the development of coronary atherosclerosis [32,33].”
Increased epicardial adipose tissue area and radiodensity in sarcopenic obesity
He, T., Wang, R., Jiang, W. W., Lian, R., Chen, X., & Yang, M. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03237-6
Zhang, Z., Lei, X., Lin, X., Xie, C., Cai, D., Weng, S., Zhao, L., Chen, M., Hou, X., & Su, K. (2026) · Science Progress · doi:10.1177/00368504261459771 · Cited by 1
Sarcopenic obesity in cirrhosis: prognostic value and future perspectives
Chen, Y., Liao, Z., Wang, C., Zhang, Y., & Huang, R. (2026) · Nutrition & Metabolism · doi:10.1186/s12986-026-01154-9
“Moreover, obesity itself is associated with the conversion of testosterone to estradiol via aromatization in adipose tissue; separately, menopausal women exhibit increased level of follicle-stimulating hormone and androgen that exacerbate the fat deposition [26, 27].”
Alpha-klotho, insulin resistance, and adiposity among older adults
Ahmad, A., Shardell, M. D., Kalyani, R. R., Semba, R. D., Mitchell, B. D., Tanaka, T., Taylor, S. I., Shrestha, A., & Ferrucci, L. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag140
“Sarcopenia, both independently and in combination with obesity, is associated with insulin resistance [57].”
Cantu-Rodriguez, M. Y., Gutiérrez-González, D., Fernández‐Chau, I. F., Trevino-Ferrer, A., Vallejo, A., Sánchez-García, A. S., Reguera‐Hernández, C., Chong, S. J. C.-V., Vázquez-Martínez, C. A., Santos-Macías, J. E., et al. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.06.009
Chen, S. H., Chou, C., Weng, S., Chen, J., & Shen, F. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70379
“Furthermore, ectopic lipid accumulation exacerbates insulin resistance, which impairs glucose uptake and protein synthesis in myocytes, ultimately contributing to sarcopenia 2, 25 – 27 .”
Yu, C., Zou, X., Dai, R., & Yang, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1876993
“Dysfunctional adipose tissue can increase in fl ammatory cytokines, adipokine imbalance, lipid-derived signals, and metabolic stress, thereby increasing the burden on local lymphatic vessels (4, 6, 9 – 12, 18, 19).”
InfluentialPark, Y. K. (2026) · 대한지역사회영양학회지 · doi:10.5720/kjcn.2026.00206
“Since human skeletal muscle is the body’s largest glucose reservoir (absorbing around 80% of total glucose) and a fat-burning organ, muscle mass decline leads to elevated blood sugar levels and visceral obesity [21].”
Niu, Y., Chen, F., Wu, R., Liu, M., Deng, S., Wang, C., Jiang, H., Zhu, J., & Jin, Y. (2026) · Scientific Reports · doi:10.1038/s41598-026-61144-y
Huo, J., Li, F., Wang, T., Tang, S., Xi, Y., & Xie, G. (2026) · Journal of Nutrition and Metabolism · doi:10.1155/jnme/1195681
“…who demonstrated in a Chinese adult population ( ≥ 45 years) that IR mediates approximately 11.78% of the total efect on low muscle mass. Accounting for 40%–50% of adult lean mass, skeletal muscle is a tissue sensitive to insulin [31–33] and the main location for glucose uptake mediated by insulin.”
InfluentialVajdi, M., Nikrad, N., Khajeh, M., Noshadi, N., Maroofi, M., Darzi, M., Tabrizi, F. P. F., & Askari, G. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02225-w
“Evidence show that insulin resistance and obesity contribute to increased inflammation [11, 12], on the other hand IR may increase de novo hepatic lipogenesis, exacerbating the fat accumulation in the liver [13].”
Liu, J., Jiao, X., Liu, L., Chen, A., Kang, Q., Guo, J., Wang, Y., Qi, Y., & You, L. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1816286
Gu, Z., Mou, C., Chen, F., Zhou, K., Li, Q., Fu, S., ZHENG, S., Li, S., & Peng, R. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1880656 · Cited by 1
“Diabetes provides a metabolic milieu for the development of SO through insulin resistance, chronic low-grade inflammation, hormonal dysregulation, and lipid metabolism abnormalities, thereby accelerating disease progression (9).”
Frigerio, F., & Donini, L. M. (2026) · Endocrinology · doi:10.1007/978-3-030-71067-5_23-1
Bai, M., & Yan, T. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02028-w
“In adults with diabetes, where obesity, inflammation, insulin resistance, and reduced lean mass may coexist, such a composite signal may still be clinically informative, but it should be interpreted as part of a broader body-composition and metabolic assessment [4, 6, 7, 32, 33].”
Zhang, R., Yu, D., Liu, X., Xue, H., Xie, J., & Wang, L. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02247-4
“Consequently, SO is associated with a higher likelihood of more advanced CKM stages within the CKM continuum that may warrant closer clinical monitoring compared with obesity alone [11, 66, 67].”
Rachma, N., Zulizar, A. A., & Rohmani, A. (2026) · JIKES Jurnal Ilmu Kesehatan · doi:10.71456/jik.v5i1.2402
“…massa otot karena mengurangi aliran darah ke otot, fungsi mitokondria, dan sensitivitas insulin pada lansia DM. Indeks Massa Tubuh (IMT) rendah (underweight) berhubungan dengan defisit energi dan protein, meningkatkan risiko sarcopenia, sementara IMT tinggi memicu inflamasi [Hong & Choi, 2020].”
Review on the Relationship Between TyG Index and CVD Incidence in Patients With T2DM With NAFLD
Zhu, Y., Yu, B., Huang, H., & Zhong, Z. (2026) · International Journal of Endocrinology · doi:10.1155/ije/6707256
“Consequently, IR and infammation create a detrimental cycle that accelerates the progression of T2DM with NAFLD and other metabolic illnesses amid lipid toxicity [45].”
ÖZER, Y. P., Güner, M., Karaduman, D., Eşme, M., Balcı, C., Doğu, B. B., Cankurtaran, M., & Halil, M. G. (2026) · Nutrition in Clinical Practice · doi:10.1002/ncp.70166
“44 47 – 50 The specific biomarkers and underlying pathophysiological mechanisms have not yet been fully clarified.”
Sinclair, A., James, F., Muraleedharan, A., & Abdelhafiz, A. H. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16080422
Hou, S., Wu, M.-H., Gao, Y.-T., Ren, Y., Yang, M., & Li, M. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-06445-w
Aging-, obesity-, and diabetes-related sarcopenia: Pathogenesis and interventions
Han, S., Xiong, Q., 吴庆前, Han, C., Zhang, Y., Zou, J., Guo, R., Gao, Y., & Meng, Z.-X. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004152
“[106] The skeletal muscle mass to visceral fat area ratio is negatively correlated with the 10-year risk of CVD in patients with T2DM; [107] lower skeletal muscle mass to visceral fat area ratio values are associated with a higher 10-year CVD risk and a greater likelihood of developing sarcopenia.”
Santoso, A. H., Firmansyah, Y., Sari, T., Martin, A., Priyana, A., Wijaya, B. A., Dinali, D., Dzakwan, M. F., Endarti, A. T., Ernawati, et al. (2026) · Obesities · doi:10.3390/obesities6050060
“…with sarcopenic obesity, with individuals in the highest tertile having a 1.82-fold higher risk compared to those in the lowest tertile [53], and up to 3.369-fold in males and 3.157-fold in females in other analyses [52], emphasizing the central role of insulin resistance in this phenotype [58,59].”
InfluentialGou, X., Zhu, J., Feng, X., Li, D., Gao, Q., & Ruan, B. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1938860
Wang, X., Song, S., Li, C., Wang, B., Dai, M., Xue, T., & Jiang, Y. (2026) · Research Square · doi:10.21203/rs.3.rs-10467646/v1
Гринкевич, М. В., Чернякова, Ю. В., & Kutsenko, Y. A. (2026) · Military Medicine · doi:10.51922/2074-5044.2026.3.18
Acierno, C., Cavallo, M., D’Ardes, D., Boccatonda, A., Nilo, D., & Caturano, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27188063 · Cited by 1
“This plausibly reflects a compounded mitochondrial and inflammatory burden in skeletal muscle that exceeds the sum of either process alone [104].”
El-Oueslati, H., Youssef, L., Manuel, R. F. J., Boucher, L., Tannou, T., Brodeur, C., Andriamampionona, F., Kergoat, M., & Aubertin‐Leheudre, M. (2026) · medRxiv · doi:10.64898/2026.09.06.26359363
Toroptsova, N. V., Dobrovolskaya, O. V., Volkov, A. V., Sorokina, A. O., & Demin, N. V. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-268
Huang, X., Duan, J., Liang, X., Li, Y., & Zhao, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1923121
“SMI, as a body size – adjusted indicator of muscle mass, is closely linked to metabolic health, physical independence, and long-term prognosis, and its deterioration re fl ects not only sarcopenia progression but also the cumulative burden of insulin resistance and chronic in fl ammation (27, 28).”
Eighty Years After Vague: Advances in Understanding Ectopic Fat and Metabolic Dysfunction
Conte, C., Sumithran, P., le Roux, C. W., Miras, A. D., & Gaal, L. V. (2026) · Obesity Reviews · doi:10.1111/obr.70229
Zhang, Z.-J., Wang, B.-B., Qu, L., & Huang, B.-P. (2026) · Scientific Reports · doi:10.1038/s41598-026-71656-2
Ma, Z., Zhang, X., Leng, Y., & Chen, X. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1954630
“In early or non-cirrhotic disease, visceral adiposity, hepatic lipid stress, muscle insulin resistance/myosteatosis, and reduced activity form a bidirectional metabolic network (38 – 43, 49, 59, 60, 70, 77, 96).”
InfluentialLiu, Z., Ren, X., Su, C., Wang, G., & Liu, J. (2026) · Healthcare · doi:10.3390/healthcare14193228 · Cited by 1
“As a surrogate marker for both central obesity and insulin resistance (IR) [9,10], CMI has been validated by accumulating evidence for its predictive value in metabolic abnormalities and atherosclerotic cardiovascular diseases [11–13].”
Chaudhari, H. R., Chaudhary, G. A., Gaikwad, Y. B., & Gaikwad, A. (2026) · Geriatric Care · doi:10.4081/gc.2026.15195
“22,23”
Cline, M., Paalani, M., Beeson, W. L., & Medina, E. (2026) · Journal of American College Health · doi:10.1080/07448481.2026.2744901
Velasteguí, C. S. V. (2026) · Revista Multidisciplinar Epistemología de las Ciencias · doi:10.71112/q5wz7d96
Wang, Z., Lin, C., Xie, Y., Huang, L., Xiao, S., Chen, H., Ge, H., Zhou, Y., Chen, J., Wu, W., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1937778
“Intramuscular fat deposition can impair insulin signaling pathways through in fl am-mation and oxidative stress and further promote muscle atrophy; in turn, the reduction in muscle mass shrinks the glucose-disposal tissue pool, exacerbating IR and perpetuating a vicious cycle (3, 4).”
Sarcopenic Obesity and Falls in Older Adults: A Narrative Review
Yan, W., & Zhou, B. (2026) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2026.1410006
Rajan, R., Cherian, K. E., Paul, T., Asha, H. S., Jose, A., Rebekah, G. J., Thomas, N., & Kapoor, N. (2026) · Aging Medicine · doi:10.1002/agm2.70120
“Furthermore, in individuals with obesity, adipose tissue-dependent metabolic derangements further predispose to sarcopenia [5].”
Metadata
- Authors
- Hong, S.-H., & Choi, K. M.
- Affiliations
- Korea University (KR)
- Corresponding author
- Choi, Kyung Mook
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-01-13
- Volume
- 21
- Issue
- 2
- Pages
- 494
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7013734
- OpenAlex
- W2999215393
- Cited by
- 390
- References
- 153
- Citations by year
- 2026: 91 · 2025: 87 · 2024: 68 · 2023: 72 · 2022: 40 · 2021: 20 · 2020: 11
- FWCI
- 4.59
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Korea Christian University (Q1625561)
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- sarcopenic obesity, insulin resistance, cardiometabolic disease, type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular disease, muscle atrophy, mitochondrial dysfunction, oxidative stress, myokines, adipokines, insulin signaling, aging
- MeSH terms
- Animals, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Mitochondria, Liver, Mitochondria, Muscle, Obesity, Sarcopenia, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.